American Thoracic Society (ATS) 2021

Virtual 14 May 2021 - 19 May 2021

Budesonide-albuterol lowers exercise-induced bronchoconstriction in patients with asthma

25 Jun 2021 by

Treatment with a fixed-dose combination of budesonide and albuterol (BDA) in a single pressurized metered-dose inhaler (pMDI), also known as PT027, significantly prevents exercise-induced bronchoconstriction (EIB) in adolescents and adults with asthma, according to the TYREE* study presented at ATS 2021.

Budesonide-albuterol lowers exercise-induced bronchoconstriction in patients with asthma

25 Jun 2021

Dupilumab may reduce exacerbations in paediatric uncontrolled asthma

22 Jun 2021 by

Children with uncontrolled moderate-to-severe asthma may benefit from treatment with dupilumab which reduced exacerbations and improved lung function, according to results of the phase III VOYAGE study presented at ATS 2021.

Dupilumab may reduce exacerbations in paediatric uncontrolled asthma

22 Jun 2021

COPD tied to excess death risk, even in younger adults

15 Jun 2021 by

Younger adults with chronic obstructive pulmonary disease (COPD) have excess risk of morbidity and mortality, contrary to common belief that the disease is mild at younger age, according to a longitudinal, population-base cohort study presented at the ATS 2021 Meeting.

COPD tied to excess death risk, even in younger adults

15 Jun 2021

PAP-treated sleep apnoea tied to reduced COVID-19 risk

14 Jun 2021 by

Individuals with obstructive sleep apnoea (OSA) may have an increased risk of COVID-19, with the risk reducing with adherence to positive airway pressure (PAP) therapy, according to a study presented at ATS 2021.

PAP-treated sleep apnoea tied to reduced COVID-19 risk

14 Jun 2021

Antibody cocktail cuts hospitalization, death in COVID-19

12 Jun 2021 by

The REGN-COV2 monoclonal antibody cocktail comprising casirivimab and imdevimab significantly reduces the risk of hospitalization and all-cause death by 71 percent compared with placebo in nonhospitalized patients with COVID-19, according to a large phase III study presented at the ATS 2021 Meeting.

Antibody cocktail cuts hospitalization, death in COVID-19

12 Jun 2021

Inhaled treprostinil tied to favourable outcomes in PH-ILD

11 Jun 2021 by

In post hoc analyses of the phase III INCREASE trial presented at ATS 2021, patients on inhaled treprostinil (iTre) for pulmonary hypertension due to parenchymal lung disease (PH-ILD) were less inclined to have multiple clinical worsening events and more likely to experience clinical improvement vs those on placebo.

Inhaled treprostinil tied to favourable outcomes in PH-ILD

11 Jun 2021

Tocilizumab administration for severe COVID-19: Timing matters

09 Jun 2021 by

Early administration (ie, pre-intubation/noninvasive ventilation) of the interleukin-6 receptor blocker tocilizumab in patients with severe COVID-19 led to more favourable outcomes compared with late administration (ie, post-intubation/noninvasive ventilation), according to data presented at ATS 2021.

Tocilizumab administration for severe COVID-19: Timing matters

09 Jun 2021

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

06 Jun 2021 by

The specific TSLP* inhibitor tezepelumab significantly reduces exacerbation rates across a broad spectrum of patients with severe, uncontrolled asthma, regardless of the status of key inflammatory biomarkers, according to the NAVIGATOR study presented at ATS 2021.

NAVIGATOR: Smooth sailing for tezepelumab in severe asthma

06 Jun 2021

Long-term study findings reflect potential of sotatercept for PAH

04 Jun 2021 by

The efficacy and safety of the novel, first-in-class, selective fusion protein sotatercept were sustained or enhanced for up to 48 weeks when added to standard of care (SOC) for the treatment of pulmonary arterial hypertension (PAH), according to interim findings of the ongoing open-label extension (OLE) period of the phase II PULSAR trial presented at ATS 2021.

Long-term study findings reflect potential of sotatercept for PAH

04 Jun 2021